Phospholipase A2 and small, dense low-density lipoprotein

Current Opinion in Lipidology

Volumn 11, Issue 5, 2000, Pages 465-471

  Hurt Camejo, Eva ^a   Camejo, Germán ^b   Sartipy, Peter ^a  

^a UNIVERSITY OF GOTHENBURG   (Sweden)

^b ASTRAZENECA R AND D   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLESTEROL; LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; PHOSPHOLIPASE A2; PHOSPHOLIPID; PROTEOGLYCAN; PHOSPHOLIPASE A;

ATHEROGENESIS; ATHEROSCLEROSIS; CORONARY ARTERY DISEASE; EXTRACELLULAR MATRIX; HUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN CONFORMATION; PROTEIN EXPRESSION; PROTEIN INTERACTION; REVIEW; RISK FACTOR; ANIMAL; ARTERIOSCLEROSIS; BLOOD; CARDIOVASCULAR DISEASE; CHEMISTRY; PARTICLE SIZE; SECRETION;

ANIMALS; ARTERIOSCLEROSIS; CARDIOVASCULAR DISEASES; HUMANS; LIPOPROTEINS, LDL; PARTICLE SIZE; PHOSPHOLIPASES A; PROTEOGLYCANS;

EID: 0033626551     PISSN: 09579672     EISSN: None     Source Type: Journal    
DOI: 10.1097/00041433-200010000-00004     Document Type: Review

References (70)

1. Potential involvement of type II phospholipase A2 in atherosclerosis
2. Modification of plasma lipoproteins by group IIA phospholipase A2: Possible implications for atherogenesis
3. The growing phospholipase A2 superfamily of signal transduction enzymes
4. Cloning and recombinant expression of a novel mouse-secreted phospholipase A2
5. Cloning and characterization of novel mouse and human secretory phospholipase A2
6. Receptors for growing family of secreted phospholipases A2
7. Novel human secreted phospholipase A2 with homology to the group III bee venom enzyme
8. Interfacial catalysis: The mechanism of phospholipase A2
9. 2 at 2.2 Å resolution
10. Interfacial enzymology of glycerolipid hydrolases: Lessons from secreted phospholipase A2
11. Phosphatidylcholine hydrolysis is required for pancreatic cholesterol esterase- and phospholipase A2-facilitated cholesterol uptake into intestinal Caco-2 cells
12. 2
13. Action of human group IIa secreted phospholipase A2 on cell membranes. Vesicle but not heparinoid binding determines rate of fatty acid release by exogenously added enzyme
14. Exogenously added human group X secreted phospholipase A2 but not the group IB, IIA, and V enzymes efficiently release arachidonic acid from adherent mammalian cells
15. Molecular basis for the association of group IIA phospholipase A2 and decorin in human atherosclerotic lesions
16. 2 in human atherosclerotic plaques
17. 2 in normal and atherosclerotic arteries: Activity of the isolated enzyme on low density lipoprotein
18. Expression of phospholipase A2 isoforms in human normal and atherosclerotic arterial wall
19. Ultrastructural localization of secretory type II phospholipase A2 in atherosclerotic and nonatherosclerotic regions of human arteries
20. IFN-gamma induces secretory group IIA phospholipase A2 in human arterial smooth muscle cells. Involvement of cell differentiation, STAT-3 activation and modulation byother cytokines
21. Interleukin 1 beta induces type II-secreted phospholipase A2 gene in vascular smooth muscle cells by a nuclear factor kB and peroxisome proliferator-activated receptor-mediated process
22. Expression of secretory group IIA phospholipase A2 in relation to the presence of microbial agents, macrophage infiltrates, and transcripts of proinflammatory cytokines in human aortic tissues
23. Serum phospholipase A2 in inflammatory diseases
24. 2 gene expression in human hepatoma cells by mediators of the acute phase response
25. Association of small low-density lipoprotein particles with the incidence of coronary artery disease in men and women
26. Low density lipoprotein particle size and risk factors of insulin resistance syndrome
27. Lipoprotein atherogenicity: An overview of current mechanisms
28. Lipoprotein heterogeneity and apolipoprotein B metabolism
29. Differences in LDL subspecies involve alterations in lipid composition and conformational changes in apolipoprotein B
30. Influence of plasma lipid and LDL-subfraction profile on the interaction between low density lipoprotein with human arterial wall proteoglycans
31. Possible functional interactions of apolipoprotein B-100 segments that associate with cell proteoglycans and the apoB/apoE receptor
32. Association of apoB lipoproteins with arterial proteoglycans: Pathological significance and molecular basis
33. Sialic acid-containing components of lipoproteins influence lipoprotein-proteoglycan interactions
34. Accumulation of lipoprotein fractions and subfractions in the arterial wall, determined in an in vitro perfusion system
35. Initiation of atherosclerosis lesions in cholesterol-fed rabbits, I: Focal increases in arterial LDL concentration precede development of fatty streak lesions
36. Phospholipase A2-modification of low density lipoproteins forms small, high density particles with increased affinity for proteoglycans and glycosaminoglycans
37. Evidence for a new pathophysiological mechanism for coronary artery disease regression. Hepatic lipase-mediated changes in LDL density
38. Differential uptake of proteoglycan-selected subfractions of low density lipoprotein by human macrophages
39. Greater oxidative suscpetibility of the surface monolayer in small, dense LDL may contribute to differences in cooper-induced oxidation among LDL subfractions
40. Enzymatic modification of low density lipoprotein by purified lipoxygenase plus phospholipase A2 mimics cell-mediated oxidative modification
41. Secretory phospholipase A2 and lipoprotein lipase enhance 15-lipoxygenase-induced enzymatic and non-enzymatic lipid peroxidation in low-density lipoproteins
42. Phospholipase A2-modified LDL is taken up at ehanced rate by macrophages
43. Discrete subspecies of human low density lipoproteins are heterogeneous in their interaction with the cellular LDL receptor
44. Small dense low density lipoprotein has increased affinity for LDL receptor-independent cell surface binding site: A potential mechanism for increased atherogenicity
45. Lipolysis of LDL with phospholipase A2 alters the expression of selected ApoB-100 epitopes and the interaction of LDL with cells
46. Sphingomyelinase induces aggregation and fusion, but phospholipase A2 only aggregation, of low density lipoprotein particles
47. ApoB-100 has a pentapartite structure composed of three amphipathic alpha-helical domains alternating with two amphipathic beta-strand domains. Detection by the computer program LOCAT
48. Evidence for lipid-dependent structural changes in specific domains of apolipoprotein B-100
49. Cellular consequences of the association of apoB lipoproteins with proteoglycans
50. Binding of a synthetic apolipoprotein B-100 peptide and peptide analogues to chondroitin-6-sulfate: Effect of the lipid environment
51. Binding of human phospholipase A2 type II to proteoglycans: Differential effect of glycosaminoglycans on enzyme activity
52. Interfacial binding of secreted phospholipases A2: More than electrostatics and a major role for tryptophan
53. 2
54. Molecular packing of high-density and low-density lipoprotein surface lipids and apolipoprotein A-I binding
55. Lipoproteins are substrates for human secretory group IIA phospholipase A2: Preferential hydrolysis of acute phase HDL
56. Secretory sphingomyelinase, a product of the acid sphingomyelinase gene, can hydrolyse atherogenic lipoproteins at neutral pH
57. Lipoprotein lipase (LPL) strongly links native and oxidized low density lipoprotein particles to decorin-coated collagen: Roles for both monomeric and dimeric forms of LPL
58. Phospholipase A2 modification enhances lipoprotein(a) binding to the subendothelial matrix
59. Effect of phospholipase A2 digestion on the conformation and lysine/fibrinogen binding properties of human lipoprotein(a)
60. Proteoglycans contribution to association of Lp(a) and LDL with smooth muscle cell extracellular matrix
61. Extent of inflammation predicts cardiovascular disease and overall mortality in seropositive rheumatoid arthritis. A retrospective cohort study from disease onset
62. Atherosclerosis an inflammatory disease
63. A modified form of low density lipoprotein with increased electronegative charge is present in rheumatoid synovial fluid
64. Inflammatory and atherogenic lipoprotein markers in patients with rheumatoid arthritis [abstract]
65. Circulating levels of secretory type II phospholipase A2 predict coronary events in patients with coronary artery disease
66. Secretory phospholipase A2 and lipoprotein lipase enhance 15-lipoxygenase-induced enzymic and nonenzymic lipid paroxidation in low density lipoproteins
67. A novel endothelial-derived lipase that modulates HDL metabolism
68. Role of group II secretory phospholipase A2 in atherosclerosis. 2. Potential involvement of biologically active oxidized phospholipids
69. Overexpression of secretory phospholipase A2 causes rapid catabolism and altered tissue uptake of high density lipoprotein cholesteryl ester and apolipoprotein A-I
70. Remodelling of high density lipoproteins by plasma factors